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Background: Near infrared-guided indocyanine green (ICG) fluorescence has vast potential for guiding sentinel
lymph node biopsy (SLNB) in patients with breast cancer. The purpose of this study was to evaluate any additional
clinical benefit for SLNB when blue dye is used in combination with ICG.
Methods: Between November of 2009 and September of 2013, 86 patients diagnosed with breast cancer were
investigated by SLNB using a combination of patent blue and ICG. A lymph node was considered as the sentinel
lymph node (SLN) when it was stained with blue dye and/or fluorescence. A levelIandIIaxillary dissection was
performed for verification of axillary node status after the SLNB.
Results: The SLN identification rate of SLN for ICG-patent blue combination was comparable to that for ICG alone
(98.8% versus 93%; P = 0.054), but the false-negative rate was reduced from 12% (3/25) to 4% (1/25). Twenty-four
patients had positive SLNs. In two of those patients, although there were SLNs identified by both tracers, the
positive SLNs were identified by blue dye only.
Conclusion: Although blue dye did not improve the identification rate significantly, there was a definite benefit in
improving the false-negative rate. The use of a fluorescence method together with blue dye is an ideal method for
hospitals that do not have access to conventional radiation-based detection methods.
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Axillary lymph node status has consistently been shown
to be the most significant prognostic factor in patients
with breast cancer [1-4]. The method of sentinel lymph
node biopsy (SLNB) is now well accepted for evaluation
of axillary node status.
Large validated studies including the ALMANAC trials
have shown that SLNB in patients with breast cancer is a
safe, reliable technique that stages the axilla accurately
[5,6].
SLNB has been performed using different techniques: in-
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unless otherwise stated.of both. Although high rates of sentinel lymph node (SLN)
detection have been obtained with all of these methods,
there is no general consensus about the optimal technique
[7,8]. The average rate of SLN identification using blue dye
or radioactive colloid is over 90%, but ranges from 65 to
98% [9]. Some surgeons use the blue dye method alone.
Although the dye method has several benefits including
ease of use, cost effectiveness and safety, it has been
pointed out that the detection rate is lower than that of the
gamma probe method, and combined mapping with radio-
colloid and blue dye has been shown to be superior to blue
dye alone [7].
Preoperative lymphoscintigraphy facilitates intraopera-
tive identification of axillary nodes, but there are con-
cerns about limited availability and cost of radiocolloids,
and the exposure of healthcare professionals to radiation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Sentinel lymph node biopsy (SLNB) using indocyanine
green fluorescence imaging: (a) The periareolar injection site and
afferent lymphatic duct were clearly observed. (b) A skin incision
was made at the point where the fluorescence disappeared and a
strong fluorescence could be seen easily after incision. (c) A
lymphatic flow in the axilla was identified. (d) The resected SLNs
with fluorescence imaging were reconfirmed by the photodynamic
eye (PDE).
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cannot clearly visualize the lymphatic drainage pathway.
Some studies have reported that indocyanine green
(ICG) could be used for SLNB in breast cancer [11,12].
The photodynamic eye (PDE) can visualize the lymph-
atic drainage pathway clearly and demonstrate the accur-
ate location of SLN real-time in the operating room
[13]. However, little is known to date about SLNB by
combining ICG with other tracers in breast cancer.
The aim of this study is to evaluate whether there is
an additional benefit to using blue dye in addition to
ICG fluorescence in breast cancer, to provide a founda-
tion for improvement of the SLNB method.
Methods
Patients
Eighty-six consecutive patients diagnosed with breast
cancer between November 2009 and September 2013
underwent SLNB using a combination of patent blue and
ICG at the Breast Centre of Dalian Central Hospital. All
patients were women with early stage breast cancer. Ex-
clusion criteria included: palpable axillary lymph nodes,
tumour diameter > 3 cm, multicentric tumour, previous
breast or axillary surgery, pregnancy, and allergy to iod-
ine or shellfish. Written consent was obtained from all
participants, and the study was approved by the institu-
tional ethics committee of Dalian Central Hospital.
Operative procedure
SLNB was performed before wide excision, breast con-
serving surgery, or mastectomy as follows. Under anaes-
thesia, 2 mL patent blue (Bleu Patente V, Guerbet,
Brussels, Belgium) was injected into the subareolar re-
gion and skin overlying the tumour. The whole breast
was massaged for about 5 minutes, then 1 mL of 1:20 di-
luted ICG solution (Diagnogreen, Daiichi Pharmaceuti-
cals, Tokyo, Japan) was injected into the subareolar
region followed by a 30-second breast massage to facili-
tate the absorption of ICG into the lymph vessels. At the
end of the massage, the surgical lights were turned off.
Image acquisition was performed under near-infrared
light (NIR, λ = 760 nM) using a photodynamic eye (Ha-
mamatsu City, Japan). The fluorescence emitted by ICG
was followed in the direction of the areola towards the
axilla, allowing visualisation of the subcutaneous lymph-
atic drainage pathway. A marking was made on the skin
where the fluorescent signal disappeared, and a skin in-
cision was made at that point.
After the subdermal layer was removed, the lymphatic
duct identified by ICG was visible. To avoid lymphatic
fluid retention, the main lymphatic duct was ligated at a
site proximal to the first SLN, because ligating the affer-
ent lymphatic vessel prevents ICG from accumulating
in the operative field. At this point, further fluorescentimaging was performed to identify any sites that emitted
a strong fluorescence, and such sites were removed
along with the surrounding tissue. Following ICG-
assisted dissection, the surgical lights were turned on
and blue-stained nodes were excised under the naked
eye. All fluorescent and/or blue-stained SLNs were har-
vested (Figure 1). A standard level I and II axillary
lymph node dissection (ALND) was performed for veri-
fication of axillary node status after SLNB. Immediately
after harvesting, SLNs were sent to the pathology de-
partment for intraoperative frozen section evaluation.
All SLNs were histopathologically evaluated by 3-mm
sectioning and staining with H&E. All SLNB procedures
were performed or supervised by two senior breast sur-
geons. Formalin-fixed paraffin embedded tissue sections
of SLNs and non-SLNs were stained with H&E.
Patient data were entered prospectively into a database
and statistically analysed using SPSS software (SPSS,
Chicago, IL, USA). A Chi-square test was used to deter-
mine statistical significance. A P-value of ≤ 0.05 was con-
sidered to be statistically significant.
Results
Patient data are shown in Table 1. The mean age was
52.6 years old (range: 32 to 76 years). The primary
tumour was located on the right for 40 cases (46.5%)
and on the left for 46 cases (53.5%). None of the 86 pa-
tients experienced adverse effects in response to ICG or
patent blue. ICG fluorescence imaging and/or blue stain-
ing identified at least one SLN in all but one patient
Table 1 Clinical characteristics of the 86 women
undergoing surgery for breast cancer
Characteristic Number (%)





















HER2/neu: human epidermal growth factor receptor-2.
Table 2 Sentinel lymph node status as determined by
fluorescence navigation, blue dye, and a combination of
both in 86 patients
Fluorescence
navigation (%)
Combination of blue dye
and fluorescence (%)
P
SLN identified 80 (93.0) 85 (98.8) 0.054
Positive lymph
node
25 (29.1) 25 (29.1)
Positive SLN 22 (25.6) 24 (27.9)
Accuracy 77 of 80 (96.2) 84 of 85 (98.8) 0.283
False-negative
rate




SLN: sentinel lymph node; Chi-square test.
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confirmed that there was no positive lymph node. The
SLN identification rate was 98.8% (85/86 patients). A
total of 291 SLNs were identified: 36 were fluorescent,
10 were blue and 245 were both fluorescent and blue. In
5 patients, SLNs were identified by patent blue alone,
and in 15 they were identified by ICG alone. Therefore,
if patent blue alone was used for the procedure, the
identification rate would have been 81.4% (70/86). In
contrast, if ICG alone was used, the identification rate
would have been 93.0% (80/86). There was no significant
difference between ICG-patent blue combination and
ICG alone on SLN identification (98.8% versus 93.0%;
P = 0.054) (Table 2).
Metastatic involvement of SLNs was identified by
ICG-patent blue in 24 of 25 patients with positive lymph
nodes. There was one false-negative case. In this patient,
we found only one SLN with no metastases, which was
both fluorescent and blue, but ALND revealed that there
were two positive axillary nodes. In two of 24 patients
with positive SLNs, although SLNs were identified with
both ICG and/or patent blue, the positive SLNs were
identified with blue dye alone. In the first patient in
whom two SLNs were found, there was a positive SLNdetected by patent blue alone, and there was a negative
SLN that was both fluorescent and blue, but ALND of
this patient revealed that there were two additional posi-
tive lymph nodes. In the second patient, we only de-
tected two SLNs that were negative and both of them
were fluorescent and blue, but her ALND demonstrated
one positive lymph node.
As mentioned, in 2 of the 24 patients with positive
SLNs, the nodes were identified with blue dye only. In
contrast, there were three patients whose positive SLNs
were identified with ICG only. If blue dye alone was used,
the positive lymph nodes would have been missed in 4
patients, resulting in a false-negative rate of 16% (4/25).
If ICG was used, the positive lymph nodes would have
been missed in 3 patients, resulting in a false-negative
rate of 12% (3/25). As described above, a positive SLN for
the combination was only missed in a single patient giv-
ing a false-negative rate of 4% (1/25). In addition, the
average number of SLNs detected in the combined group
was high compared to that in the ICG group (3.6 versus
2.4, Table 2).
Discussion
Lymphography, in preparation for SLNB, has come to
the fore as a major field of application in lymphatic im-
aging for malignant neoplasia with potential lymph
nodal spread and has had a significant impact on overall
prognosis [14,15]. SLNB is an accepted method for sta-
ging axillary lymph nodes in women with early breast
cancer, and different advantages and disadvantages are
associated with different tracer methods. Some advocate
blue dye alone, others radioisotope (RI) only, and many
utilized a combination of both. Some studies have dem-
onstrated improved identification rate and lower false-
negative rate using a combination of blue dye and RI
[16]. McMasters et al. [17] reported an identification
rate of 98.0% and a false-negative rate of 6.5% with the
combination of RI (dermal injection) and isosulfan blue
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to detect SLNs in breast cancer patients, and a combined
use of the two tracers has yielded a high diagnostic value.
Now, the combination method is a standard technique.
However, the use of a radiotracer is associated with sig-
nificant expense and requires radiation measures, and RI
is not generally available. Some clinicians have used blue
dye alone to perform SLNB in breast cancer and the SLN
identification rate was always about 85% by using the
method, suggesting that the lower identification rate was
not related to the surgeon’s experience but is intrinsic to
the technique [18].
ICG as a tracer has been shown to be safe in over
40 years of clinical usage [19,20]. Kitai et al. [21] reported
the use of fluorescent imaging with ICG during SLNB for
breast cancer. Fluorescence-guided imaging with ICG
involves advantages compared to the conventional
methods, including the combination of transcutaneous
and in situ navigation, real-time lymphography, a low in-
cidence of adverse reactions of ICG as well as a SLNB
procedure without radioactive tracers but a high sensitiv-
ity [10]. Moreover, a significant risk of anaphylactic reac-
tion from the blue dye could be spared [22].
However, little is known to date about SLNB com-
bined with ICG and other tracers in breast cancer. The
purpose of this study was to determine whether there is
an added benefit from using blue dye with ICG when
performing SLNS in breast cancer. In this study, all
SLNs were identified exclusively by bright fluorescence
and/or dye labeling (Figure 1). ICG-guided SLNs re-
sulted in a detection rate of 93.0%, and the identification
rate of SLNs using ICG with blue dye was 98.8%, similar
to or better than those reported by other researchers,
which were obtained by the gamma probe or the com-
bined method that used the gamma probe and the dye
[23]. There was no obvious difference in the SLN identi-
fication rate between ICG alone and ICG in combination
with patent blue (P = 0.054) (Table 2). The SLN identifi-
cation rate was acceptable using either ICG or using a
combination of agents. In one patient out of eighty-six
cases without any SLN detected, a faint track to medias-
tinal lymph nodes but without a clear path to the axilla
was observed. When axillary dissection was performed,
we could not find any fluorescent and/or blue-stained
lymph nodes in the patient and there were no positive
lymph nodes. In this study, lymph nodes existing outside
the axilla were not examined and because the patient
was a case with an internal mammary route, we did not
find the SLN in the axilla.
McMasters et al. [17] also found that the dual-agent
technique resulted in a lower false-negative rate com-
pared to the single agent that was used in their study. In
the present study, when SLNB was guided by only the
fluorescent method, the false-negative rate was 12%,which created a risk of missing appropriate SLNs in the
patients. However, by the combination method it was 4%.
A false-negative rate of greater than 5% is unacceptable,
and thus, even though the blue dye only improved the
identification rate by 5%, the false-negative rate was
reduced from 12% to the clinically acceptable rate of 4%.
Although the false-negative rates would not be statisti-
cally different between ICG used alone and the combin-
ation method because of the relatively small numbers of
false-negative results, there was a trend for improved
false-negative rate for using blue dye in addition to ICG
fluorescence, which may be clinically meaningful. The
results show that there was a higher false-negative rate if
the fluorescent technique was used alone, but by using a
combination method, it would be acceptable.
In our study, ICG fluorescence with blue dye identified
a mean of 3.6 SLNs per patient and the accuracy was
98.8%. In contrast, use of ICG-guided method alone
identified only a mean of 2.4 SLNs per patient (Table 2).
In the procedure, we tried to remove more SLNs
because recent publication has shown that the examin-
ation of two nodes provides 91 to 98% accuracy of nodal
status, whereas the examination of 4 nodes provides
accuracy greater than 98% [24].
There is a learning curve involved in effective per-
formance of SLNB [25,26]. That is, SLNs can be de-
tected more rapidly and precisely as the surgeon gains
more experience of cases requiring SLNB. The blue dye
method is helpful in training surgical residents and other
surgeons who are learning how to perform the proced-
ure [27]. An advantage of ICG fluorescence is that it en-
ables visualization of lymph flow from the breast to the
axilla. SLNs were identified and resected more rapidly
and easily by introducing fluorescence and the method
was particularly beneficial in difficult cases where SLNs
were not readily identified using the dye method [28].
Thus, it can be said that SLNB using ICG fluorescence
could be very useful. A disadvantage of ICG fluorescence
is that leakage and pollution of ICG causes halation of
the image, that is, a glow associated with ICG leakage in
the entire surgical field shown in a fluorescence image.
When the first SLN is removed and the associated
lymphatic ducts have been cut, ICG spreads to the surgi-
cal field making it difficult to detect another fluorescent
node. This problem can be solved by ligating the main
lymphatic duct at a site proximal to the first SLN to
avoid lymphatic fluid retention, because ligating the af-
ferent lymphatic vessel prevents ICG from accumulating
in the operative field [24].
Conclusions
The combination of ICG fluorescence with visible patent
blue dye is a highly sensitive method for SLN identifica-
tion during SLNB in breast cancer staging, with a clinically
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ation. The dual-tracer method would be particularly useful
in institutions where radiotracers availability is limited.
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